ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028

ADC Therapeutics SA

Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.
Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.
LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.
LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.
IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.